Literature DB >> 16115930

Analysis of the DPYD gene implicated in 5-fluorouracil catabolism in a cohort of Caucasian individuals.

Katharina Seck1, Silvia Riemer, Ronald Kates, Tobias Ullrich, Verena Lutz, Nadia Harbeck, Manfred Schmitt, Marion Kiechle, Robert Diasio, Eva Gross.   

Abstract

PURPOSE: Complete or partial loss of dihydropyrimidine dehydrogenase (DPD) function has been described in cancer patients with intolerance to fluoropyrimidine drugs like 5-fluorouracil (5-FU) or Xeloda. The intention of this population study is to assess and to evaluate gene variations in the entire coding region of the dihydropyrimidine dehydrogenase gene (DPYD), which could be implicated in DPD malfunction. EXPERIMENTAL
DESIGN: A cohort of 157 individuals was genotyped by denaturing high-performance liquid chromatography; 100 of these genotypes were compared with functional studies on DPD activity and mRNA expression.
RESULTS: Twenty-three variants in coding and noncoding regions of the DPYD gene were detected, giving rise to 15 common haplotypes with a frequency of >1%. Rare sequence alterations included a frameshift mutation (295-298delTCAT) and three novel point mutations, 1218G>A (Met406Ile), 1236G>A (Glu412Glu), and 3067C>T (Pro1023Ser). DPD enzyme activity showed high variation in the analyzed population and correlated with DPD mRNA expression. In particular, the novel variants were not accompanied with decreased enzyme activity. However, a statistically significant deviation from the median DPD activity of the population was associated with the mutations 1601G>A (Ser534Asn) and 2846A>T (Asp949Val).
CONCLUSION: This work presents an analysis of DPYD gene variations in a large cohort of Caucasians. The results reflect the genetic and enzymatic variability of DPD in the population and may contribute to further insight into the pharmacogenetic disorder of DPD deficiency.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16115930     DOI: 10.1158/1078-0432.CCR-04-1784

Source DB:  PubMed          Journal:  Clin Cancer Res        ISSN: 1078-0432            Impact factor:   12.531


  29 in total

Review 1.  Part 2: pharmacogenetic variability in drug transport and phase I anticancer drug metabolism.

Authors:  Maarten J Deenen; Annemieke Cats; Jos H Beijnen; Jan H M Schellens
Journal:  Oncologist       Date:  2011-05-31

Review 2.  Pharmacogenetics research on chemotherapy resistance in colorectal cancer over the last 20 years.

Authors:  Mariusz Panczyk
Journal:  World J Gastroenterol       Date:  2014-08-07       Impact factor: 5.742

3.  Quantitative Contribution of rs75017182 to Dihydropyrimidine Dehydrogenase mRNA Splicing and Enzyme Activity.

Authors:  Q Nie; S Shrestha; E E Tapper; C S Trogstad-Isaacson; K J Bouchonville; A M Lee; R Wu; C R Jerde; Z Wang; P A Kubica; S M Offer; R B Diasio
Journal:  Clin Pharmacol Ther       Date:  2017-05-26       Impact factor: 6.875

4.  DPYD variants as predictors of 5-fluorouracil toxicity in adjuvant colon cancer treatment (NCCTG N0147).

Authors:  Adam M Lee; Qian Shi; Emily Pavey; Steven R Alberts; Daniel J Sargent; Frank A Sinicrope; Jeffrey L Berenberg; Richard M Goldberg; Robert B Diasio
Journal:  J Natl Cancer Inst       Date:  2014-11-07       Impact factor: 13.506

5.  Pharmacogenetic variants associated with outcome in patients with advanced gastric cancer treated with fluoropyrimidine and platinum-based triplet combinations: a pooled analysis of three prospective studies.

Authors:  D Meulendijks; E A Rozeman; A Cats; K Sikorska; M Joerger; M J Deenen; J H Beijnen; J H M Schellens
Journal:  Pharmacogenomics J       Date:  2016-12-20       Impact factor: 3.550

6.  Phenotypic profiling of DPYD variations relevant to 5-fluorouracil sensitivity using real-time cellular analysis and in vitro measurement of enzyme activity.

Authors:  Steven M Offer; Natalie J Wegner; Croix Fossum; Kangsheng Wang; Robert B Diasio
Journal:  Cancer Res       Date:  2013-01-17       Impact factor: 12.701

7.  Genetic variations and haplotype structures of the DPYD gene encoding dihydropyrimidine dehydrogenase in Japanese and their ethnic differences.

Authors:  Keiko Maekawa; Mayumi Saeki; Yoshiro Saito; Shogo Ozawa; Kouichi Kurose; Nahoko Kaniwa; Manabu Kawamoto; Naoyuki Kamatani; Ken Kato; Tetsuya Hamaguchi; Yasuhide Yamada; Kuniaki Shirao; Yasuhiro Shimada; Manabu Muto; Toshihiko Doi; Atsushi Ohtsu; Teruhiko Yoshida; Yasuhiro Matsumura; Nagahiro Saijo; Jun-Ichi Sawada
Journal:  J Hum Genet       Date:  2007-09-09       Impact factor: 3.172

8.  Association between DPYD c.1129-5923 C>G/hapB3 and severe toxicity to 5-fluorouracil-based chemotherapy in stage III colon cancer patients: NCCTG N0147 (Alliance).

Authors:  Adam M Lee; Qian Shi; Steven R Alberts; Daniel J Sargent; Frank A Sinicrope; Jeffrey L Berenberg; Axel Grothey; Blase Polite; Emily Chan; Sharlene Gill; Morton S Kahlenberg; Suresh G Nair; Anthony F Shields; Richard M Goldberg; Robert B Diasio
Journal:  Pharmacogenet Genomics       Date:  2016-03       Impact factor: 2.089

9.  Intragenic deletions and a deep intronic mutation affecting pre-mRNA splicing in the dihydropyrimidine dehydrogenase gene as novel mechanisms causing 5-fluorouracil toxicity.

Authors:  André B P van Kuilenburg; Judith Meijer; Adri N P M Mul; Rutger Meinsma; Veronika Schmid; Doreen Dobritzsch; Raoul C M Hennekam; Marcel M A M Mannens; Marion Kiechle; Marie-Christine Etienne-Grimaldi; Heinz-Josef Klümpen; Jan Gerard Maring; Veerle A Derleyn; Ed Maartense; Gérard Milano; Raymon Vijzelaar; Eva Gross
Journal:  Hum Genet       Date:  2010-08-29       Impact factor: 4.132

10.  Strong association of a common dihydropyrimidine dehydrogenase gene polymorphism with fluoropyrimidine-related toxicity in cancer patients.

Authors:  Eva Gross; Birgit Busse; Matthias Riemenschneider; Steffi Neubauer; Katharina Seck; Hanns-Georg Klein; Marion Kiechle; Florian Lordick; Alfons Meindl
Journal:  PLoS One       Date:  2008-12-23       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.